期刊文献+

Cognitive changes associated with ADT: a review of the literature 被引量:1

Cognitive changes associated with ADT: a review of the literature
下载PDF
导出
摘要 The use of androgen deprivation therapy (ADT) has increased since the early 1990s after early detection efforts and greater use of the prostate-specific antigen (PSA) test. Although ADT is associated with favorable clinical outcomes, ADT has been associated with an increased risk for cardiovascular disease, increased serum cholesterol, triglycerides, insulin resistance, body mass index and fat body mass. Here we review findings from 11 clinical studies examining the effects of ADT on cognition as measured by standardized tests in cognitive domains such as verbal and spatial memory. Most of these studies have important limitations, including small sample sizes, suboptimal control groups and baseline group differences in confounding factors. Despite these limitations, the best designed studies, those comparing patients on ADT to healthy controls, generally suggest that spatial memory might be especially sensitive to the effects of ADT. Critically, to date there is only one study involving random assignment of ADT versus close clinical observation. That study revealed a decrease in verbal memory with ADT, but was limited in sample size and did not include a measure of spatial memory. A recent observational study revealed no substantial evidence of cognitive impairment with ADT, even in the domain of verbal memory. Like the randomizedstudy, however, this large observational study lacked a measure of spatial memory. Overall, the studies with the best controls suggest a potential negative impact of ADT on spatial memory, and perhaps verbal memory, and a need for continued investigation of the impact of ADT on cognition, particularly in these two cognitive domains. The use of androgen deprivation therapy (ADT) has increased since the early 1990s after early detection efforts and greater use of the prostate-specific antigen (PSA) test. Although ADT is associated with favorable clinical outcomes, ADT has been associated with an increased risk for cardiovascular disease, increased serum cholesterol, triglycerides, insulin resistance, body mass index and fat body mass. Here we review findings from 11 clinical studies examining the effects of ADT on cognition as measured by standardized tests in cognitive domains such as verbal and spatial memory. Most of these studies have important limitations, including small sample sizes, suboptimal control groups and baseline group differences in confounding factors. Despite these limitations, the best designed studies, those comparing patients on ADT to healthy controls, generally suggest that spatial memory might be especially sensitive to the effects of ADT. Critically, to date there is only one study involving random assignment of ADT versus close clinical observation. That study revealed a decrease in verbal memory with ADT, but was limited in sample size and did not include a measure of spatial memory. A recent observational study revealed no substantial evidence of cognitive impairment with ADT, even in the domain of verbal memory. Like the randomizedstudy, however, this large observational study lacked a measure of spatial memory. Overall, the studies with the best controls suggest a potential negative impact of ADT on spatial memory, and perhaps verbal memory, and a need for continued investigation of the impact of ADT on cognition, particularly in these two cognitive domains.
出处 《Asian Journal of Andrology》 SCIE CAS CSCD 2012年第2期232-238,共7页 亚洲男性学杂志(英文版)
关键词 androgen deprivation therapy COGNITION prostate cancer androgen deprivation therapy cognition prostate cancer
  • 相关文献

参考文献55

  • 1Ferlay J, Shin HR, Bray F, Forman 0, Mathers C et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 10. Lyon: International Agency for Research on Cancer; 2010. http://globocan.iarc.fr.
  • 2Barry MJ, Delorenzo MA, Walker-Corkery ES, Lucas FL, Wennberg DC. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int2006; 98: 973-8.
  • 3Saylor P J, Smith MR. Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. J Natl Compr Canc Netw 2010; 8: 211-23.
  • 4Tammela T. Endocrine treatment of prostate cancer. J Steroid Biochem Mol Biol 2004; 92: 287-95.
  • 5Shahinian VB, Kuo VF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer2005; 103: 1615-24.
  • 6Barrass BJ, Thurairaja R, Persad RA. More should be done to prevent the harmful effects of long-term androgen ablation therapy in prostate cancer. BJU Int2004; 93: 1175-6.
  • 7Wilson LS, Tesoro R, Elkin EP, Sadetsky N, BroeringJM etal. Cumulative cost pattern comparison of prostate cancer treatments. Cancer 2007; 109: 518-27.
  • 8Grossmann M, Zajac JD. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated? Clin Endocrinol 2011; 74: 289-93.
  • 9Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen?deprivation therapy in men with prostate cancer. Cancer 2009; 115: 2388-99.
  • 10Cancer Facts &Figures 2011. Atlanta, GA: American Cancer Society; 2011.

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部